Ann: Application for quotation of securities - CHM, page-16

Shares on issue and price are directly tied to market cap—it’s basic math.

But here’s the point: with the massive overhang now, like it or not, this is going to weigh on price action.

People like you have been saying there’s "a lot to like" about this company since 2021. And yet, what’s happened? It’s slid from 34 cents to 0.7 cents. That’s not just a drop—it’s a nosedive.

There’s no urgency for anyone to jump in right now. The reality? We’re looking at endless sell pressure around $0.007–$0.008. It’s hard to see how it climbs out of that range anytime soon.

Sure, there’s a lot to like—if you’re Paul Hopper or one of the doctors. They’re getting their paydays and performance rights while shareholders are left holding the bag, diluted at rock-bottom prices.